Esperion Therapeutics
(NASDAQ) ESPR
Esperion Therapeutics Financials at a Glance
Market Cap
$814.31M
Revenue (TTM)
$418.24M
Net Income (TTM)
-$7.42M
EPS (TTM)
-$0.10
P/E Ratio
-30.53
Dividend
$0.00
Beta (Volatility)
1.02 (Average)
Dividend
$0.00
Beta (Volatility)
1.02 (Average)
Price
$3.16
Volume
7,960
Open
$3.16
Price
$3.16
Volume
7,960
Open
$3.16
Previous Close
$3.16
Daily Range
$3.16 - $3.16
52-Week Range
$0.95 - $4.18
Estimated Earnings Date
Aug 4, 2026
Dividend
$0.00
Beta (Volatility)
1.02 (Average)
Price
$3.16
Volume
7,960
Open
$3.16
Previous Close
$3.16
Daily Range
$3.16 - $3.16
52-Week Range
$0.95 - $4.18
Estimated Earnings Date
Aug 4, 2026
ESPR News
ESPR: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Esperion Therapeutics
Industry
Pharmaceuticals
Sector
Health CareEmployees
294
CEO
Sheldon L. Koenig, MBA
Website
www.esperion.comHeadquarters
Ann Arbor, MI 48108, US
ESPR Financials
Key Financial Metrics (TTM)
Gross Margin
65%
Operating Margin
18%
Net Income Margin
-2%
Return on Equity
0%
Return on Capital
47%
Return on Assets
-2%
Earnings Yield
-3.28%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$814.31M
Shares Outstanding
257.69M
Volume
7.96K
Avg. Volume
12.17M
Financials (TTM)
Gross Profit
$273.91M
Operating Income
$60.27M
EBITDA
$63.87M
Operating Cash Flow
-$13.09M
Capital Expenditure
$0.00
Free Cash Flow
-$13.09M
Cash & ST Invst.
$167.85M
Total Debt
$548.00M
Esperion Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$80.10M
+23.2%
Gross Profit
$45.53M
+36.1%
Gross Margin
56.84%
N/A
Market Cap
$814.31M
N/A
Market Cap/Employee
$2.68M
N/A
Employees
304
N/A
Net Income
-$25.20M
+37.7%
EBITDA
-$44.97M
-114.1%
Quarterly Fundamentals
Total Cash
$156.16M
+36.2%
Total Debt
$252.63M
-15.2%
Accounts Receivable
$132.35M
+62.8%
Inventory
$104.21M
+4.9%
Long Term Debt
$461.36M
+92.0%
Short Term Debt
$84.14M
+46.4%
Return on Assets
-1.60%
N/A
Return on Invested Capital
46.73%
N/A
Free Cash Flow
-$27.91M
-23.3%
Operating Cash Flow
-$27.72M
-22.5%